Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis.

Javier Váquez-BourgonVíctor Ortiz-García de la FozMarcos Gómez-Revuelta Jacqueline Mayoral-van SonMaría Juncal-RuizNathalia Garrido-TorresJacqueline Mayoral-van Son

Published in: The international journal of neuropsychopharmacology (2022)

This study shows that aripiprazole and risperidone share a similar long-term metabolic profile. After 1 year of antipsychotic treatment, drug-naïve FEP patients in both treatment groups presented a significant increase in weight and metabolic changes, leading to a greater prevalence of metabolic disorders.

Keyphrases

randomized controlled trial
end stage renal disease
chronic kidney disease
newly diagnosed
physical activity
body mass index
risk factors
emergency department
peritoneal dialysis
combination therapy
electronic health record
big data
weight gain